Marc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology.
Prior to joining the Firm in 2018, Mr. Goodman was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on the large-cap and specialty pharmaceuticals sectors. Prior to UBS, Mr. Goodman covered the specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley. Mr. Goodman has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.
Mr. Goodman earned a B.A. in Economics from Tufts University and an MBA. from The Ohio State University.